Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine has inked a collaboration with Merck to develop companion diagnostic tests for use with Merck's anti-PD-1 immunotherapy drug Keytruda (pembrolizumab).

Under the agreement announced today, the companies plan to develop a pan-cancer CDx to measure microsatellite instability (MSI), CDx tests for tumor mutational burden (TMB), and other novel biomarkers of response.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Feb
05
Sponsored by
LGC

This webinar will provide a behind-the-scenes look at the collaborative development of a novel multiplex assay to speed detection of mosquito-borne illness in the clinical setting.

Feb
25
Sponsored by
Loop Genomics

This webinar will discuss a study that used long-read transcriptome sequencing to explore the distribution of isoforms in colon cancer samples and their metastasis counterparts. 

Feb
26
Sponsored by
Autogen

This webinar will explain how the Clinic for Special Children in Strasburg, Pennsylvania, has transformed its DNA workflows to improve the diagnosis and treatment of genetic illnesses that are prevalent in the pediatric population of its community.